Calciscon AG announced today the closing for its Series A financing, led by Yellowstone Holding, for CHF 2.5M. The proceeds of the financing enable the company to accelerate the introduction of its T50 test in routine clinical use in Europe, and prepare for US launch. The T50 test is a modern, first of its kind blood test, which measures calcification propensity. This information helps doctors to better guide therapies of kidney disease patients. Multiple studies indicate that T50-guided therapies slow down calcification propensity, and could significantly reduce cardiovascular complications, which remains the most common cause of morbidity and mortality among renal patients.